Myriad Genetics Inc. announced select preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with its full year 2026 financial guidance. The company expects fourth quarter 2025 total revenues to range between $207 million and $209 million, and full year 2025 total revenues to be between $822 million and $824 million. These preliminary results indicate a snapshot of the company’s recent performance, pending final audited figures to be released during its February 2026 earnings call. Myriad Genetics also introduced its financial guidance for 2026, although specific figures for 2026 were not disclosed in the provided information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623538-en) on January 12, 2026, and is solely responsible for the information contained therein.